Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients — Stella

Recruiting

Back to Non-segmental Vitiligo trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Skin Care Research, LLC, Hollywood, Florida

U Mass Chan Medical School, Worcester, Massachusetts

Taiwan

Linkou Chang Gung Memorial Hospital, Taoyuan District

Key details

Phase

Safety & dosing

Sponsor

Elixiron Immunotherapeutics (Hong Kong) Ltd.

Enrollment target

~45 participants

Started

December 2025

Primary completion

December 2026

Age range

18 Years – 65 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov